ERAS
NASDAQ HealthcareErasca, Inc. - Common Stock
Biotechnology
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
๐ Market Data
| Price | $10.03 |
|---|---|
| Volume | 9,568,769 |
| Market Cap | 3.12B |
| Beta | 1.050 |
| RSI (14-Day) | 36.5 |
| 200-Day MA | $6.82 |
| 50-Day MA | $15.69 |
| 52-Week High | $24.28 |
| 52-Week Low | $1.06 |
| Forward P/E | -17.78 |
| Price / Book | 8.77 |
๐ฏ Investment Strategy Scores
ERAS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (78/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Over-Hyped (11/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ERAS in your text
Paste any article, transcript, or post โ the tool will extract ERAS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.